Lonza Group AGLONN.SW
What Lonza Group AG does.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | CHF 6.2B | CHF 6.7B | CHF 5.5B | CHF 6.5B |
| Net income | CHF 1.2B | CHF 654.0M | CHF 636.0M | -CHF 275.0M |
| Free cash flow | -CHF 852.0M | -CHF 294.0M | -CHF 143.0M | -CHF 217.0M |
More on LONN.SW.
- Lonza Group AG summary
- Lonza Group AG financial statements
- Lonza Group AG key metrics
- Lonza Group AG health scores
- Lonza Group AG valuation
- Lonza Group AG dividends
- Lonza Group AG peers
- Lonza Group AG annual reports
Figures from Lonza Group AG's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.